Table 4

Mean FFbH after 6–24 months for completers of the initial biological therapy and for all patients (ITT analysis)

Completers onlyAll patients
nMean of FFbH at 6, 12, 18, 24 months (95% CI)Mean of FFbH at 6, 12, 18, 24 months (95% CI)nMean of FFbH at 6, 12, 18, 24 months (95% CI)Mean of FFbH at 6, 12, 18, 24 months (95% CI)
UnadjustedAdjusted*UnadjustedAdjusted*
ETA/MTX18269.9 (66.9 to 73.0)68.2 (66.1 to 70.2)30565.9 (63.4 to 68.4)65.2 (63.6 to 66.7)
ETA/LEF4971.7 (65.7 to 77.6)69.2 (65.2 to 73.1)7866.0 (61.1 to 71.0)65.6 (62.4 to 68.7)
ADA/MTX15669.8 (66.5 to 73.1)67.6 (65.2 to 69.9)27466.0 (63.4 to 68.7)65.1 (63.3 to 66.9)
ADA/LEF4067.9 (61.4 to 74.5)67.0 (62.5 to 71.4)8062.9 (58.0 to 67.8)63.0 (59.9 to 66.2)
INF/MTX11270.8 (66.8 to 74.7)71.2 (68.5 to 73.8)25065.3 (62.6 to 68.1)66.8 (65.0 to 68.6)
INF/LEF1969.2 (59.7 to 78.8)66.5 (60.2 to 72.7)5467.4 (61.4 to 73.3)64.2 (60.3 to 68.0)
MTX total68.9 (67.6 to 70.2)65.9 (64.9 to 66.8)
LEF total67.7 (64.9 to 70.6)64.1 (62.1 to 66.0)
  • *Means adjusted for disease activity score based on 28 joint counts (DAS28) at baseline, function, percentage of men, previous biological therapy, year of follow-up, year of study entry; see Statistics section.

  • ADA, adalimumab; ETA, etanercept; FFbH, Hannover functional status questionnaire; INF, infliximab; ITT, intent-to-treat; LEF, leflunomide; MTX, methotrexate.